European Medicines Agency and US FDA accept regulatory submissions for nivolumab plus ipilimumab in the first-line treatment of metastatic or recurrent non-small cell lung cancer (NSCLC)

The submissions seek approval for use of the combination, administered concomitantly with a limited course of chemotherapy, in the treatment of patients with no EGFR or ALK genomic tumour aberrations. They are based on data from the Phase III CheckMate-9LA trial.

Source:

Biospace Inc.